FDA Brief

Warning letters Drugs

FDA warning letter to

Brigham and Women’s Hospital Inc.

High riskIssued Apr 11, 2022Posted May 10, 2022Office of Pharmaceutical Quality Operations Division I

Brigham and Women’s Hospital PET drug facility had water leaks and fungal contamination in aseptic areas, FDA says.

What happened

FDA inspected the Boston facility from August 5 to September 16, 2021 and found water infiltrations and fungal organisms in ISO 5 (high-cleanliness) areas used to make PET drugs. The letter also says the hospital did not adequately clean and disinfect equipment, complete media fill qualifications on time, or investigate environmental monitoring and out-of-specification endotoxin results; one [13N]-Ammonia batch was released after an out-of-specification endotoxin result was invalidated and retested.

What FDA found

  1. The facility was not adequate to prevent contamination; water infiltrated areas around aseptic production equipment, and fungal organisms were found in ISO 5 high-cleanliness areas.

    21 CFR 212.30(a) and (b)
  2. Equipment cleaning and disinfection were inadequate: the sporicidal disinfectant contact time was not met, an operator put their head and upper torso into a biological safety cabinet during cleaning, and media fill qualifications were not completed within required periods.

    21 CFR 212.30(a) and (b)
  3. The hospital did not adequately investigate environmental monitoring results above action levels to find root causes and take effective corrective and preventive actions.

    21 CFR 212.30(a) and (b)
  4. The hospital did not adequately investigate out-of-specification endotoxin results and released a [13N]-Ammonia batch after invalidating a 30.7 EU/mL result and getting passing retests without a clear root cause.

    21 CFR 212.20(d)

What FDA wants

Provide a comprehensive contamination risk assessment, remediation plan with timelines, environmental monitoring results, corrective action plan, cleaning and disinfection evaluation, facility qualification and media fill/smoke study information, batch investigations, specifications, and a plan to ensure staff follow procedures. Also provide a retrospective review of invalidated out-of-specification results and a remediation plan for OOS investigations, and respond in writing within 15 working days.

Who should pay attention

  • other hospital-based PET drug manufacturers
  • sterile injectable manufacturers using aseptic processing
  • quality teams managing environmental monitoring and OOS investigations

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. CNC Noodle Corporation

    FDA warned CNC Noodle Corporation that its Hayward, California noodle plant had insanitary conditions, no pathogen or allergen controls, and mislabeled products.

    High risk
  2. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  3. Next Medical Products Company, LLC

    FDA warns Next Medical Products that its ultrasound gels were contaminated and made without required quality controls or clearance.

    High risk
  4. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk